Trials / Completed
CompletedNCT04996758
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
An Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab and Anlotinib | Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14. |
Timeline
- Start date
- 2021-10-30
- Primary completion
- 2023-09-30
- Completion
- 2024-12-01
- First posted
- 2021-08-09
- Last updated
- 2024-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04996758. Inclusion in this directory is not an endorsement.